Moclobemide and selegeline in the treatment of depression in Parkinson’s disease

Folstein's mini mental state examination score, patients' "on-off" diaries during five days, and the Hamilton depression rating scale (HDRS) for depression were assessed one week before and after six weeks of treatment; MMSE and HDRS were scored in the "on" state of motor response to levodopa. Moclobemide lacks anticholinergic and hepatotoxic effects, and is even able to antagonise the cognitive impairment resulting from cholinergic blockade. 6 The present study confirms the antidepressant effects of moclobemide in depressed patients with Parkinson's disease.